JP2020524519A - 全セルフリーdnaによる移植合併症リスクの評価 - Google Patents

全セルフリーdnaによる移植合併症リスクの評価 Download PDF

Info

Publication number
JP2020524519A
JP2020524519A JP2019571052A JP2019571052A JP2020524519A JP 2020524519 A JP2020524519 A JP 2020524519A JP 2019571052 A JP2019571052 A JP 2019571052A JP 2019571052 A JP2019571052 A JP 2019571052A JP 2020524519 A JP2020524519 A JP 2020524519A
Authority
JP
Japan
Prior art keywords
dna
amount
total
subject
transplant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019571052A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524519A5 (cg-RX-API-DMAC7.html
Inventor
ミッチェル,アオイ,トミタ
ミッチェル,ミカエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical College of Wisconsin
Original Assignee
Medical College of Wisconsin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical College of Wisconsin filed Critical Medical College of Wisconsin
Publication of JP2020524519A publication Critical patent/JP2020524519A/ja
Publication of JP2020524519A5 publication Critical patent/JP2020524519A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/101—Sanger sequencing method, i.e. oligonucleotide sequencing using primer elongation and dideoxynucleotides as chain terminators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2019571052A 2017-06-20 2018-06-20 全セルフリーdnaによる移植合併症リスクの評価 Pending JP2020524519A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762522533P 2017-06-20 2017-06-20
US62/522,533 2017-06-20
US201762572556P 2017-10-15 2017-10-15
US62/572,556 2017-10-15
PCT/US2018/038598 WO2018237075A1 (en) 2017-06-20 2018-06-20 Assessing transplant complication risk with total cell-free dna

Publications (2)

Publication Number Publication Date
JP2020524519A true JP2020524519A (ja) 2020-08-20
JP2020524519A5 JP2020524519A5 (cg-RX-API-DMAC7.html) 2021-07-29

Family

ID=64735781

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019571052A Pending JP2020524519A (ja) 2017-06-20 2018-06-20 全セルフリーdnaによる移植合併症リスクの評価

Country Status (8)

Country Link
US (2) US11773434B2 (cg-RX-API-DMAC7.html)
EP (2) EP3642353B1 (cg-RX-API-DMAC7.html)
JP (1) JP2020524519A (cg-RX-API-DMAC7.html)
CN (1) CN110945136A (cg-RX-API-DMAC7.html)
AU (2) AU2018288832B2 (cg-RX-API-DMAC7.html)
CA (1) CA3067637A1 (cg-RX-API-DMAC7.html)
IL (1) IL271460A (cg-RX-API-DMAC7.html)
WO (1) WO2018237075A1 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US12655483B2 (en) 2010-05-18 2026-06-16 Natera, Inc. Methods for simultaneous amplification of target loci
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
EP2854058A3 (en) 2010-05-18 2015-10-28 Natera, Inc. Methods for non-invasive pre-natal ploidy calling
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US11332793B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for simultaneous amplification of target loci
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
AU2011348100B2 (en) 2010-12-22 2016-08-25 Natera, Inc. Methods for non-invasive prenatal paternity testing
JP6153874B2 (ja) 2011-02-09 2017-06-28 ナテラ, インコーポレイテッド 非侵襲的出生前倍数性呼び出しのための方法
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
PL3117012T5 (pl) 2014-03-14 2026-03-16 Caredx, Inc. Sposoby monitorowania terapii immunosupresyjnych u biorcy przeszczepu
RU2717641C2 (ru) 2014-04-21 2020-03-24 Натера, Инк. Обнаружение мутаций и плоидности в хромосомных сегментах
US20180173845A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
EP4428863A3 (en) 2015-05-11 2024-12-11 Natera, Inc. Methods and compositions for determining ploidy
JP7280044B2 (ja) 2016-04-15 2023-05-23 ナテラ, インコーポレイテッド 肺癌の検出方法
WO2018067517A1 (en) 2016-10-04 2018-04-12 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
US10011870B2 (en) 2016-12-07 2018-07-03 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
WO2019118926A1 (en) 2017-12-14 2019-06-20 Tai Diagnostics, Inc. Assessing graft suitability for transplantation
EP3737773B1 (en) 2018-01-12 2023-04-12 Natera, Inc. Novel primers and uses thereof
DK3781714T3 (da) 2018-04-14 2026-03-30 Natera Inc Fremgangsmåder til cancerpåvisning og -overvågning ved personlig påvisning af cirkulerende tumor-dna
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
WO2020206290A1 (en) * 2019-04-03 2020-10-08 The Medical College Of Wisconsin, Inc. Methods for assessing risk using total cell-free dna
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
US12305235B2 (en) 2019-06-06 2025-05-20 Natera, Inc. Methods for detecting immune cell DNA and monitoring immune system
CN111667883B (zh) * 2020-06-03 2021-01-22 四川大学 一种基于复合微单倍型焦磷酸测序图谱解析的法医学混合dna的分析方法
WO2022099190A1 (en) * 2020-11-09 2022-05-12 The Medical College Of Wisconsin, Inc Assessing risk with pre-operative total cell-free dna
WO2025079958A1 (ko) * 2023-10-11 2025-04-17 고려대학교 산학협력단 높은 처리량의 돌연변이 특이적 아답터 리게이션 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150086477A1 (en) * 2012-04-19 2015-03-26 Medical College Of Wisconsin, Inc. Highly sensitive surveillance using detection of cell free dna
WO2016176662A1 (en) * 2015-04-30 2016-11-03 Medical College Of Wisconsin, Inc. Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cell-free dna

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004838A1 (en) 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US5319071A (en) 1987-11-25 1994-06-07 Immunex Corporation Soluble interleukin-1 receptors
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
US5645988A (en) 1991-05-08 1997-07-08 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying drugs with selective effects against cancer cells
US5569582A (en) 1991-07-15 1996-10-29 Institute Of Molecular Biology & Technology Rapid amplification and detection of nucleic acids
PE64396A1 (es) 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
ES2245085T3 (es) 1998-01-23 2005-12-16 Immunex Corporation Adn y polipeptidos acpl.
US20030148301A1 (en) 1999-12-10 2003-08-07 Toshiya Aono Method of detecting nucleotide polymorphism
DE60123448T2 (de) 2001-12-24 2007-08-23 Prof. Wolfgang Holzgreve Verfahren zur nicht-invasiven Diagnose von Transplantationen und Transfusionen
US6977162B2 (en) 2002-03-01 2005-12-20 Ravgen, Inc. Rapid analysis of variations in a genome
JP4116856B2 (ja) 2002-10-02 2008-07-09 富士フイルム株式会社 1塩基多型の検出方法
EP1599608A4 (en) 2003-03-05 2007-07-18 Genetic Technologies Ltd Identification of fetal DNA and fetal cell marker in maternal plasma or serum
US20060014179A1 (en) 2004-06-02 2006-01-19 New England Biolabs, Inc. Inferring function from shotgun sequencing data
CA2585025A1 (en) 2004-10-22 2006-05-04 Redpath Integrated Pathology, Inc. Dynamic genomic deletion expansion and formulation of molecular marker panels for integrated molecular pathology diagnosis and characterization of tissue, cellular fluid, and purefluid specimens
US8609338B2 (en) 2006-02-28 2013-12-17 University Of Louisville Research Foundation, Inc. Detecting fetal chromosomal abnormalities using tandem single nucleotide polymorphisms
SI1996728T1 (sl) 2006-02-28 2011-10-28 Univ Louisville Res Found Prepoznavanje kromosomskih nenormalnosti pri zarodku s pomočjo dvojnih mononukleotidnih polimorfizmov
US12054776B2 (en) 2007-07-23 2024-08-06 The Chinese University Of Hong Kong Diagnosing fetal chromosomal aneuploidy using massively parallel genomic sequencing
US20100326218A1 (en) 2007-09-27 2010-12-30 Michael Boeckh Identifying a subject with an increased risk of invasive mold infection
US8748113B2 (en) 2007-11-15 2014-06-10 The Johns Hopkins University Methods for detecting and monitoring circulating cancer stem cells
EP2364368B1 (en) 2008-11-07 2014-01-15 Sequenta, Inc. Methods of monitoring conditions by sequence analysis
WO2010087985A2 (en) 2009-01-28 2010-08-05 Yale University Novel markers for detection of complications resulting from in utero encounters
WO2011015944A2 (en) 2009-08-06 2011-02-10 Cedars-Sinai Medical Center Use of free dna as an early predictor of severity in acute pancreatitis
DK2496720T3 (da) 2009-11-06 2020-09-28 Univ Leland Stanford Junior Ikke-invasiv diagnose af transplantatafstødning i organ-transplanterede patienter
US20120010085A1 (en) 2010-01-19 2012-01-12 Rava Richard P Methods for determining fraction of fetal nucleic acids in maternal samples
US20130143219A1 (en) 2010-01-28 2013-06-06 Medical College of Wisconsin Inc. Methods and compositions for high yield, specific amplification
CN102892901B (zh) 2010-03-24 2015-11-25 凸版印刷株式会社 利用竞争性引物的目标碱基序列的检测方法
US20120034603A1 (en) 2010-08-06 2012-02-09 Tandem Diagnostics, Inc. Ligation-based detection of genetic variants
US10131947B2 (en) 2011-01-25 2018-11-20 Ariosa Diagnostics, Inc. Noninvasive detection of fetal aneuploidy in egg donor pregnancies
JP6153874B2 (ja) 2011-02-09 2017-06-28 ナテラ, インコーポレイテッド 非侵襲的出生前倍数性呼び出しのための方法
WO2012113780A1 (en) 2011-02-21 2012-08-30 Qiagen Gmbh Method for quantifying human dna
WO2012122374A2 (en) 2011-03-08 2012-09-13 Children's Medical Center Corporation Non-invasive methods for diagnosing chronic organ transplant rejection
WO2013090585A2 (en) 2011-12-16 2013-06-20 Basf Agrochemical Products, B.V. Methods and compositions for analyzing ahasl genes in wheat
US10077474B2 (en) 2012-05-29 2018-09-18 Abbott Molecular, Inc. Method of designing primers, method of detecting single nucleotide polymorphisms (SNPs), method of distinguishing SNPs, and related primers, detectable oligonucleotides, and kits
KR102082735B1 (ko) 2012-08-03 2020-02-28 훼링 비.브이. 암컷 불임에 대한 치료학적 타겟 및 진단 마커로서의 세포-유리 dna
GB201304810D0 (en) 2013-03-15 2013-05-01 Isis Innovation Assay
WO2014143989A1 (en) 2013-03-15 2014-09-18 Medical College Of Wisconsin, Inc. Fetal well being surveillance using fetal specific cell free dna
PL3004388T5 (pl) 2013-05-29 2023-10-09 Chronix Biomedical Wykrywanie i oznaczanie ilościowe pozakomórkowego dna dawcy w układzie krążenia biorców przeszczepów organów
CN105659091A (zh) 2013-08-19 2016-06-08 卓异生物公司 用于单分子检测的测定及其应用
CA2922746A1 (en) 2013-09-06 2015-03-12 Immucor Gti Diagnostics, Inc. Compositions and methods for diagnosis and prediction of solid organ graft rejection
WO2015069933A1 (en) 2013-11-06 2015-05-14 The Board Of Trustees Of The Leland Stanford Junior University Circulating cell-free dna for diagnosis of transplant rejection
US20170051343A1 (en) 2014-02-14 2017-02-23 The Board Of Regents Of The University Of Texas System Strand exchange hairpin primers that give high allelic discrimination
PL3117012T5 (pl) 2014-03-14 2026-03-16 Caredx, Inc. Sposoby monitorowania terapii immunosupresyjnych u biorcy przeszczepu
RU2717641C2 (ru) 2014-04-21 2020-03-24 Натера, Инк. Обнаружение мутаций и плоидности в хромосомных сегментах
US10801067B2 (en) 2014-05-09 2020-10-13 Eurofins Lifecodexx Gmbh Detection of DNA that originates from a specific cell-type and related methods
EP3164503B1 (en) 2014-07-03 2024-08-28 Agilent Technologies, Inc. Methods for non-invasive detection of transplant health or rejection
HUE068191T2 (hu) 2014-08-22 2024-12-28 Resolution Bioscience Inc A sejtmentes dns kvantitatív genetikai elemzésére szolgáló eljárások
WO2016063122A1 (en) 2014-10-20 2016-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for screening a subject for a cancer
WO2016109604A2 (en) 2014-12-29 2016-07-07 InnoGenomics Technologies, LLC Multiplexed assay for quantitating and assessing integrity of cell-free dna in biological fluids for cancer diagnosis, prognosis, and surveillance
WO2016123698A1 (en) 2015-02-06 2016-08-11 Uti Limited Partnership Diagnostic assay for post-transplant assessment of potential rejection of donor organs
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
GB2556004A (en) 2015-07-10 2018-05-16 Univ West Virginia Markers of stroke and stroke severity
CA3001698C (en) 2015-10-22 2025-01-07 Cytosorbents Corporation Sorbant in the form of porous, blood-compatible polymer beads, multifunctional for the elimination of protein-based toxins and potassium from biological fluids
AU2016363113A1 (en) 2015-12-03 2018-06-07 Alfred Health Monitoring treatment or progression of myeloma
CA3022572A1 (en) * 2016-04-29 2017-11-02 The Medical College Of Wisconsin, Inc. Multiplexed optimized mismatch amplification (moma)-target number
EA201892491A1 (ru) 2016-04-29 2019-06-28 Дзе Медикал Колледж Оф Висконсин, Инк. Пцр в реальном времени с мультиплексной оптимизированной амплификацией неправильно спаренных оснований (moma) для анализа злокачественных новообразований
BR112018072197A2 (pt) 2016-04-29 2019-02-12 Medical College Wisconsin Inc amplificação de emparelhamento optimizado múltiplo (moma) - pcr de tempo real para avaliar o poço fetal
AU2017355458A1 (en) 2016-11-02 2019-06-13 The Medical College Of Wisconsin, Inc. Methods for assessing risk using mismatch amplification and statistical methods
US20190367972A1 (en) 2016-11-02 2019-12-05 The Medical College Of Wisconsin, Inc. Methods for assessing risk using total and specific cell-free dna
US12447464B2 (en) 2016-12-22 2025-10-21 Duke University Polycationic microfibers and methods of using the same
US20210139983A1 (en) 2017-06-20 2021-05-13 The Medical College Of Wisconsin, Inc. Transplant patient monitoring with cell-free dna
CN111094593A (zh) 2017-06-20 2020-05-01 威斯康星州立大学医学院 使用供体特异性无细胞dna来评估移植对象中的病症
US20200141925A1 (en) 2017-07-07 2020-05-07 Mcmaster University Risk Assessment Tool for Patients with Sepsis
WO2019008408A1 (en) 2017-07-07 2019-01-10 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS FOR DETERMINING WHETHER A PATIENT SUFFERING FROM MYELOPROLIFERATIVE NEOPLASM IS AT RISK OF THROMBOSIS
ES2913665T3 (es) 2017-09-18 2022-06-03 Santersus Ag Método y dispositivo para la purificación de sangre a partir de ADN celular libre en circulación
MA51210A (fr) 2017-12-01 2020-10-07 Juno Therapeutics Inc Procédés de dosage et de modulation de cellules génétiquement modifiées
WO2019118926A1 (en) 2017-12-14 2019-06-20 Tai Diagnostics, Inc. Assessing graft suitability for transplantation
WO2019217918A1 (en) 2018-05-10 2019-11-14 The Medical College Of Wisconsin, Inc. Multiplexed optimized mismatch amplification (moma)-cancer risk assessment with non-cancer associated targets
US20200109449A1 (en) 2018-10-09 2020-04-09 Tai Diagnostics, Inc. Cell lysis assay for cell-free dna analysis
EP3899033A4 (en) 2018-12-17 2022-10-19 The Medical College of Wisconsin, Inc. Assessing risk with total cell-free dna
WO2020206290A1 (en) 2019-04-03 2020-10-08 The Medical College Of Wisconsin, Inc. Methods for assessing risk using total cell-free dna
CA3135853A1 (en) 2019-04-03 2020-10-08 The Medical College Of Wisconsin, Inc. Transplant patient monitoring with cell-free dna
WO2020206292A2 (en) 2019-04-03 2020-10-08 The Medical College Of Wisconsin, Inc. Assessing conditions in transplant subjects using donor-specific cell-free dna

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150086477A1 (en) * 2012-04-19 2015-03-26 Medical College Of Wisconsin, Inc. Highly sensitive surveillance using detection of cell free dna
WO2016176662A1 (en) * 2015-04-30 2016-11-03 Medical College Of Wisconsin, Inc. Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cell-free dna

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Cell-Free DNA as a Noninvasive Acute Rejection Marker in Renal Transplantation", CLINICAL CHEMISTRY, vol. Volume 55, Issue 11, JPN6022011968, 2009, pages 1958 - 1966, ISSN: 0004889020 *
"Quantification of Circulating Cell-Free DNA in Pediatric Heart Transplant Recipients", THE JOURNAL OF HEART AND LUNG TRANSPLANTATION, vol. Volume 30, Issue 4, JPN6022011966, 2011, pages 139 - 407, ISSN: 0004889021 *
ACTA PAEDIATRICA, vol. 96, JPN6023027208, 2007, pages 644 - 647, ISSN: 0005100406 *
医学図書館, vol. 51, no. 4, JPN6023027207, 2004, pages 387 - 388, ISSN: 0005100405 *

Also Published As

Publication number Publication date
US20210139969A1 (en) 2021-05-13
CA3067637A1 (en) 2018-12-27
CN110945136A (zh) 2020-03-31
US20240026437A1 (en) 2024-01-25
EP4488387A3 (en) 2025-07-23
US11773434B2 (en) 2023-10-03
EP3642353B1 (en) 2025-03-05
AU2025204208A1 (en) 2025-06-26
EP3642353C0 (en) 2025-03-05
EP4488387A2 (en) 2025-01-08
AU2018288832B2 (en) 2025-03-06
EP3642353A4 (en) 2021-02-24
EP3642353A1 (en) 2020-04-29
IL271460A (en) 2020-01-30
AU2018288832A1 (en) 2020-01-16
WO2018237075A1 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
US20240026437A1 (en) Assessing transplant complication risk with total cell-free dna
JP7323462B2 (ja) セルフリーdnaによる移植患者のモニタリング
US20220267849A1 (en) Transplant patient monitoring with cell-free dna
US20230167499A1 (en) Methods for assessing risk using total cell-free dna
US20220356522A1 (en) Assessing conditions in transplant subjects using donor-specific cell-free dna
EP3535413B1 (en) Methods for assessing risk using total and specific cell-free dna
US20210139988A1 (en) Assessing conditions in transplant subjects using donor-specific cell-free dna
WO2020131955A1 (en) Assessing risk with total cell-free dna
JP2019534017A (ja) ミスマッチ増幅を使用するリスクを評価するための方法および統計方法
HK40029115B (en) Assessing transplant complication risk with total cell-free dna
HK40029115A (en) Assessing transplant complication risk with total cell-free dna

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220328

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220330

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230405

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230705